Genmab A/S (GMAB)
NASDAQ: GMAB
· Real-Time Price · USD
20.82
-0.21 (-1.00%)
At close: May 23, 2025, 3:59 PM
20.70
-0.55%
After-hours: May 23, 2025, 05:05 PM EDT
-1.00% (1D)
| Bid | 20.2 |
| Market Cap | 13.02B |
| Revenue (ttm) | 18.1B |
| Net Income (ttm) | 6.71B |
| EPS (ttm) | 1.7 |
| PE Ratio (ttm) | 12.24 |
| Forward PE | 1.62 |
| Analyst | Buy |
| Ask | 21.4 |
| Volume | 1,034,142 |
| Avg. Volume (20D) | 1,517,550 |
| Open | 20.52 |
| Previous Close | 21.03 |
| Day's Range | 20.52 - 20.82 |
| 52-Week Range | 17.23 - 28.96 |
| Beta | 0.90 |
About GMAB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GMAB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GMAB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+2.65%
Genmab A/S shares are trading higher after the com...
Unlock content with
Pro Subscription
2 months ago
-8.95%
Genmab shares are trading lower after Johnson & Johnson decided not to exercise its option to receive a worldwide license to develop, manufacture, and commercialize HexaBody-CD38. Genmab will not pursue further clinical development.
